TY - JOUR
T1 - Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflammation in a rat model of inflammatory bowel disease
AU - Elli, Luca
AU - Ciulla, Michele M.
AU - Busca, Giuseppe
AU - Roncoroni, Leda
AU - Maioli, Claudio
AU - Ferrero, Stefano
AU - Bardella, Maria Teresa
AU - Bonura, Antonella
AU - Paliotti, Roberta
AU - Terrani, Claudia
AU - Braidotti, Paola
PY - 2011/3
Y1 - 2011/3
N2 - Inflammatory bowel disease (IBD) represents a socially and clinically relevant disorder, characterized by intestinal chronic inflammation. Cystamine (CysN) is a multipotent molecule with healthy effects and, moreover, it is an inhibitor of transglutaminases (TGs), including the TG type 2 (TG2), an enzyme with pleiotropic functions, involved in different pathways of inflammation and central in the pathogenesis of some human disorders as the IBD. Our aim was to evaluate the effect of CysN in an IBD rat model. A total of 30 rats were divided into 4 groups: controls without treatment (CTR; n7); receiving the 2,4,6-trinitrobenzene sulfonic acid enema (TNBS group; n8); treated with TNBS enema plus oral CysN (TNBS-CysN group; n8); treated with CysN (CysN group; n7). After killing, bowel inflammation was evaluated applying specific scores. TG activity, TG2 and isopeptide bond immunohistochemical expression, and tumor necrosis factor-α (TNF-α) were evaluated in the colonic tissue, such as interleukin-6 (IL-6) serological levels (ELISA). TG2 was also evaluated on the luminal side of the colon by immunoautoradiography. Colonic samples from IBD patients were compared with animal results. TNBS-CysN group developed a less severe colitis compared with the TNBS group (macroscopic score 0.43±0.78 vs 3.28±0.95, microscopic score 6.62±12.01 vs 19.25±6.04, P
AB - Inflammatory bowel disease (IBD) represents a socially and clinically relevant disorder, characterized by intestinal chronic inflammation. Cystamine (CysN) is a multipotent molecule with healthy effects and, moreover, it is an inhibitor of transglutaminases (TGs), including the TG type 2 (TG2), an enzyme with pleiotropic functions, involved in different pathways of inflammation and central in the pathogenesis of some human disorders as the IBD. Our aim was to evaluate the effect of CysN in an IBD rat model. A total of 30 rats were divided into 4 groups: controls without treatment (CTR; n7); receiving the 2,4,6-trinitrobenzene sulfonic acid enema (TNBS group; n8); treated with TNBS enema plus oral CysN (TNBS-CysN group; n8); treated with CysN (CysN group; n7). After killing, bowel inflammation was evaluated applying specific scores. TG activity, TG2 and isopeptide bond immunohistochemical expression, and tumor necrosis factor-α (TNF-α) were evaluated in the colonic tissue, such as interleukin-6 (IL-6) serological levels (ELISA). TG2 was also evaluated on the luminal side of the colon by immunoautoradiography. Colonic samples from IBD patients were compared with animal results. TNBS-CysN group developed a less severe colitis compared with the TNBS group (macroscopic score 0.43±0.78 vs 3.28±0.95, microscopic score 6.62±12.01 vs 19.25±6.04, P
KW - colitis
KW - cystamine
KW - inflammatory bowel disease
KW - transglutaminase type 2
UR - http://www.scopus.com/inward/record.url?scp=79952078818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952078818&partnerID=8YFLogxK
U2 - 10.1038/labinvest.2010.186
DO - 10.1038/labinvest.2010.186
M3 - Article
C2 - 21042292
AN - SCOPUS:79952078818
VL - 91
SP - 452
EP - 461
JO - Laboratory Investigation
JF - Laboratory Investigation
SN - 0023-6837
IS - 3
ER -